[The use of moxonidine in patients with essential hypertension combined with metabolic syndrome].
Syrtlanova
E R
ER
Gil'mutdinova
L T
LT
D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001786:Blood Glucose / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D007093:Imidazoles / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D007705:Kinins / Q000097:blood / Q000187:drug effects; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000150:complications*; D008875:Middle Aged; D020842:Plasma Kallikrein / Q000187:drug effects; D013931:Thromboxanes / Q000097:blood
D000959:Antihypertensive Agents; D001786:Blood Glucose; D007093:Imidazoles; D007328:Insulin; D007705:Kinins; D013931:Thromboxanes; C043482:moxonidine; D020842:Plasma Kallikrein